ASH 2021 | The impact of daratumumab induction on stem cell collection in myeloma patients
Natalie Callander
• 13 Dec 2021
Natalie Callander, MD, University of Wisconsin School of Medicine and Public Health, Madison, WI, briefly compares stem cell collection in the MASTER trial (NCT03224507) versus the GRIFFIN trial (NCT02874742) with the aim of evaluating the impact of daratumumab induction on stem cell collection for transplant. Dr Callander explains that whether granulocyte colony-stimulating factor (G-CSF) was used with plerixafor automatically or as rescue plerixafor, there was no negative impact of daratumumab on the ability to collect stem cells. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
